Terumo Cardiovascular Systems announced that it has entered into an exclusive agreement with LAAx to distribute the TigerPaw system II, a left atrial appendage closure device in the USA.
The TigerPaw system II is indicated for occlusion of the left atrial appendage under direct visualisation, in conjunction with other open cardiac procedures. It is new to the market following successful completion of a clinical trial. During its clinical trial the TigerPaw system II provided 100% occlusion at both post-op and at 90 days.
